Current status of alpha-fetoprotein testing

Gastroenterology and Hepatology

Volumn 7, Issue 2, 2011, Pages 113-114

  Sherman, Morris ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN;

CANCER DIAGNOSIS; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; ECHOGRAPHY; HUMAN; LABORATORY TEST; LIVER CELL CARCINOMA; NOTE; PATIENT MONITORING; PROTEIN BLOOD LEVEL; SCREENING TEST; TESTIS CANCER;

EID: 79952802702     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (5)

1. Sherman M. The resurrection of alphafetoprotein. J Hepatol. 2010;52:939-940.
2. Tateyama M, Yatsuhashi H, Taura N, et al. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol. 2011;46:92-100.
3. Sterling RK, Jeffers L, Gordon F, et al. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2009;7:104-113.
4. Lok AS, Sterling RK, Everhart JE, et al; HALT-C Trial Group. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarken for the early detection of hepatocellular carcinoma. Gastroenterology. 2010;138:493-502.
5. Sterling RK, Jeffers L, Gordon F, et al. Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol. 2007;102:2196-2205. (Pubitemid 47493844)